A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma

Annals of Oncology

Volumn 27, Issue 5, 2016, Pages 947-952

  Thomas, S ^a   Aggarwal, R ^a   Jahan, T ^a   Ryan, C ^a   Troung, T ^a   Cripps, A M ^a   Raha, P ^a   Thurn, K T ^a   Chen, S ^a   Grabowsky, J A ^a   Park, J ^a   Hwang, J ^a   Daud, A ^a   Munster, Pamela N ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Epirubicin; Histone deacetylase; Panobinostat; Sarcoma; Topoisomerase

Indexed keywords

EPIRUBICIN; GLUCOSE; HISTONE; PANOBINOSTAT; GYRASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; INDOLE DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GLUCOSE BLOOD LEVEL; HISTONE ACETYLATION; HUMAN; HUMAN CELL; LEUKOPENIA; LIVER DYSFUNCTION; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SARCOMA; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VOMITING; CHROMATIN; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DNA REPAIR; DOSE RESPONSE; DRUG EFFECTS; GENETICS; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; CHROMATIN; DNA REPAIR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EPIRUBICIN; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INDOLES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; SARCOMA; TOPOISOMERASE II INHIBITORS;

EID: 84964770221     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw044     Document Type: Article

References (24)

1. Bramwell VH. Management of advanced adult soft tissue sarcoma. Sarcoma 2003; 7: 43-55.
2. Zunino F, Capranico G. DNA topoisomerase II as the primary target of anti-tumor anthracyclines. Anticancer Drug Des 1990; 5: 307-317.
3. Antman K, Crowley J, Balcerzak SP et al. A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. Cancer 1998; 82: 1288-1295.
4. Edmonson JH, Ryan LM, Blum RH et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993; 11: 1269-1275.
5. van der Graaf WT, Blay JY, Chawla SP et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012; 379: 1879-1886.
6. Schöffski P, Maki RG, Italiano A et al. Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI). J Clin Oncol 2015; 33: Supplemental Abstr LBA 10502.
7. Thurn KT, Thomas S, Moore A, Munster PN. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol 2011; 7: 263-283.
8. Marchion DC, Bicaku E, Daud AI et al. In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. Mol Cancer Ther 2005; 4: 1993-2000.
9. Lopez G, Liu J, Ren W et al. Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma. Clin Cancer Res 2009; 15: 3472-3483.
10. Sampson ER, Amin V, Schwarz EM et al. The histone deacetylase inhibitor vorinostat selectively sensitizes fibrosarcoma cells to chemotherapy. J Orthop Res 2011; 29: 623-632.
11. Thurn KT, Thomas S, Raha P et al. Histone deacetylase regulation of ATMmediated DNA damage signaling. Mol Cancer Ther 2013; 12: 2078-2087.
12. Munster P, Marchion D, Bicaku E et al. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin Cancer Res 2009; 15: 2488-2496.
13. Munster P, Marchion D, Bicaku E et al. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 2007; 25: 1979-1985.
14. Bennani-Baiti IM. Epigenetic and epigenomic mechanisms shape sarcoma and other mesenchymal tumor pathogenesis. Epigenomics 2011; 3: 715-732.
15. Pacheco M, Nielsen TO. Histone deacetylase 1 and 2 in mesenchymal tumors. Mod Pathol 2012; 25: 222-230.
16. Su L, Sampaio AV, Jones KB et al. Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics. Cancer Cell 2012; 21: 333-347.
17. Hrzenjak A, Moinfar F, Kremser ML et al. Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Mol Cancer Ther 2006; 5: 2203-2210.
18. Sakimura R, Tanaka K, Yamamoto S et al. The effects of histone deacetylase inhibitors on the induction of differentiation in chondrosarcoma cells. Clin Cancer Res 2007; 13: 275-282.
19. Hrzenjak A, Moinfar F, Kremser ML et al. Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo. Mol Cancer 2010; 9: 49.
20. Munster PN, Thurn KT, Thomas S et al. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer 2011; 104: 1828-1835.
21. Munster PN, Marchion D, Thomas S et al. Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br J Cancer 2009; 101: 1044-1050.
22. Marchion DC, Bicaku E, Daud AI et al. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem 2004; 92: 223-237.
23. Wolf JL, Siegel D, Goldschmidt H et al. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk Lymphoma 2012; 53: 1820-1823.
24. Van Glabbeke M, Verweij J, Judson I et al. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002; 38: 543-549.